49.65MMarket Cap-1371P/E (TTM)
0.644High0.611Low166.55KVolume0.630Open0.629Pre Close104.48KTurnover0.23%Turnover RatioLossP/E (Static)79.94MShares2.30052wk High3.55P/B45.23MFloat Cap0.51052wk Low--Dividend TTM72.83MShs Float103.050Historical High--Div YieldTTM5.20%Amplitude0.510Historical Low0.627Avg Price1Lot Size
BioLine Rx Stock Forum
BioLineRx Announces Multi-Center Phase 1 Trial Sponsored By St. Jude Children's Research Hospital To Evaluate Motixafortide For CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications In Sickle Cell Disease
BioLine Rx (NASDAQ: $BLRX), an Israeli biopharmaceutical development company, recently received a reiterated buy rating from the renowned investment bank, HC Wainwright & Co. The financial institution has maintained a price target of $21 for BioLine Rx, indicating a positive outlook for the company's futur...
presentation for (2) drugs news to be issued soon
Alpha.Scorpio 💪🏻🏆
No comment yet